Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $40.20.

Several equities analysts recently commented on the company. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Citigroup upped their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $23.57 on Tuesday. The company has a market cap of $2.68 billion, a PE ratio of -13.78 and a beta of 0.78. Zai Lab has a 12 month low of $15.96 and a 12 month high of $36.77. The company has a 50-day simple moving average of $18.88 and a 200-day simple moving average of $19.29.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The firm had revenue of $106.31 million during the quarter. On average, analysts anticipate that Zai Lab will post -2.23 EPS for the current year.

Insider Activity at Zai Lab

In other Zai Lab news, Director William Lis sold 7,040 shares of Zai Lab stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $18.09, for a total value of $127,353.60. Following the transaction, the director owned 50,437 shares in the company, valued at $912,405.33. This trade represents a 12.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ying Du sold 7,026 shares of Zai Lab stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $18.53, for a total transaction of $130,191.78. Following the completion of the transaction, the chief executive officer owned 1,203,784 shares in the company, valued at approximately $22,306,117.52. This trade represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 90,873 shares of company stock worth $1,730,096. 4.88% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC raised its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.